Disease stage in Alzheimer disease and treatment effects of rivastigmine

Alexander Kurz, Martin Farlow, Peter Quarg, René Spiegel

Research output: Contribution to journalArticle

46 Scopus citations


The efficacy and tolerability of the cholinesterase inhibitor rivastigmine in the treatment of Alzheimer disease (AD) have been demonstrated in several clinical trials, which included patients with a wide range of dementia severities. To investigate the association between severity of disease and treatment response, the combined data from three large randomized, placebo-controlled trials were analyzed. The pooled patient population was stratified into three cohorts showing moderately severe (Mini-Mental State Examination score [MMSE] ≤ 15), moderate (MMSE 16-22), and mild (MMSE ≥ 22) dementia. In each cohort, the effects of rivastigmine 6 to 12 mg/day versus placebo were evaluated using the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) and the Progressive Deterioration Scale. Rivastigmine 6 to 12 mg/day maintained ADAS-cog scores at or above placebo levels in all cohorts, while cognitive deterioration with placebo was progressive and severity dependent. Activities of daily living showed statistically significant benefits with rivastigmine across all severity cohorts.

Original languageEnglish (US)
Pages (from-to)123-128
Number of pages6
JournalAlzheimer disease and associated disorders
Issue number3
StatePublished - Jul 1 2004


  • Clinical trial
  • Rivastigmine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Disease stage in Alzheimer disease and treatment effects of rivastigmine'. Together they form a unique fingerprint.

  • Cite this